The estimated Net Worth of James G. Marken is at least $13.1 Milión dollars as of 7 June 2024. Mr. Marken owns over 12,550 units of ANI Pharmaceuticals Inc stock worth over $7,002,717 and over the last 11 years he sold ANIP stock worth over $4,735,344. In addition, he makes $1,398,770 as Senior Vice President - Operations and Product Development at ANI Pharmaceuticals Inc.
Sign up
Mr. Marken ANIP stock SEC Form 4 insiders trading
James has made over 13 trades of the ANI Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 12,550 units of ANIP stock worth $661,385 on 7 June 2024.
The largest trade he's ever made was selling 24,338 units of ANI Pharmaceuticals Inc stock on 7 March 2024 worth over $1,615,313. On average, James trades about 2,825 units every 76 days since 2014. As of 7 June 2024 he still owns at least 128,916 units of ANI Pharmaceuticals Inc stock.
You can see the complete history of Mr. Marken stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Marken biography
James G. Marken serves as Senior Vice President - Operations and Product Development of the Company. Mr. Marken joined ANIP in March 2007 as General Manager of the Minnesota facilities and served as ANIP’s Vice President, Operations and Product Development from March 2009 until June 2013 when he became the Company’s Vice President, Operations. As Senior Vice President, Operations and Product Development, Mr. Marken has been principally responsible for the following areas: manufacturing, packaging, engineering/maintenance, purchasing, warehousing and product development. Mr. Marken brings over 30 years of pharmaceutical industry experience to the Company. Prior to joining ANIP in March 2007, he worked for Solvay Pharmaceuticals as plant manager and in various departments including quality control, validation and manufacturing. Mr. Marken holds a B.S. degree in Chemistry from Bemidji State University.
What is the salary of James Marken?
As the Senior Vice President - Operations and Product Development of ANI Pharmaceuticals Inc, the total compensation of James Marken at ANI Pharmaceuticals Inc is $1,398,770. There are 2 executives at ANI Pharmaceuticals Inc getting paid more, with Robert Schrepfer having the highest compensation of $2,160,980.
How old is James Marken?
James Marken is 57, he's been the Senior Vice President - Operations and Product Development of ANI Pharmaceuticals Inc since 2016. There are 7 older and 7 younger executives at ANI Pharmaceuticals Inc. The oldest executive at ANI Pharmaceuticals Inc is Thomas Penn, 73, who is the Independent Director.
What's James Marken's mailing address?
James's mailing address filed with the SEC is C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE, MN, 56623.
Insiders trading at ANI Pharmaceuticals Inc
Over the last 11 years, insiders at ANI Pharmaceuticals Inc have traded over $183,421,501 worth of ANI Pharmaceuticals Inc stock and bought 96,741 units worth $2,783,357 . The most active insiders traders include Arthur Przybyl, Venture Partners Ii Lp Meri... a Muthusamy Shanmugam. On average, ANI Pharmaceuticals Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,378,805. The most recent stock trade was executed by Meredith Cook on 13 August 2024, trading 250 units of ANIP stock currently worth $14,905.
What does ANI Pharmaceuticals Inc do?
ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.
What does ANI Pharmaceuticals Inc's logo look like?
Complete history of Mr. Marken stock trades at ANI Pharmaceuticals Inc
ANI Pharmaceuticals Inc executives and stock owners
ANI Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Robert Schrepfer,
Senior Vice President - New Business Development and Specialty Sales -
Stephen Carey,
Corporate Secretary, Vice President, Finance and Chief Financial Officer -
James Marken,
Senior Vice President - Operations and Product Development -
James G. Marken,
Sr. VP of Operations & Product Devel. -
Robert Brown,
Independent Director -
Thomas Haughey,
Independent Director -
Thomas Penn,
Independent Director -
Patrick Walsh,
Chairman of the Board -
David Nash,
Independent Director -
Jeanne Thoma,
Independent Director -
Antonio Pera,
Independent Director -
Nikhil Lalwani,
President, Chief Executive Officer, Director -
Muthasamy Shanmugam MS R.Ph.,
Head of R&D and COO of Novitium Operations -
Ori Gutwerg,
Sr. VP of Generics -
Christopher K. Mutz,
Head of Rare Diseases -
Chad Gassert,
Sr. VP of Corp. Devel. & Strategy -
Daniel Raynor,
Director -
Arthur Przybyl,
President and CEO -
Tracy Marshbanks,
Director -
Fred Holubow,
Director -
Peter A Lankau,
Director -
Charlotte C. Arnold,
Chief Financial Officer -
Renee P Tannenbaum,
Director -
Ross J Mangano,
Director -
Robert J. Jamnick,
VP, Quality & Product Develop. -
Venture Partners Ii Lp Meri...,
-
Ori Gutwerg,
SVP, GENERICS -
Christopher Mutz,
HEAD OF RARE DISEASE -
Krista Davis,
SVP, CHIEF HR OFFICER -
Chad Gassert,
SVP - CORP. DEV. & STRATEGY -
Meredith Cook,
SR. VP, GENERAL COUNSEL & SEC. -
Muthusamy Shanmugam,
HEAD OF R&D, COO-NOVITIUM OPS -
Matthew J Leonard,
Director